Related Experiment Video

Updated: Aug 18, 2026

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
09:22

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry

Published on: August 13, 2021

Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase

Ivana Vucenik1, Gayatri Ramakrishna, Kwanchanit Tantivejkul

  • 1Department of Medical and Research Technology, University of Maryland School of Medicine, 100 Penn Street, Baltimore, MD 21201, USA ivucenik@umaryland.edu

Breast Cancer Research and Treatment
|May 4, 2005
PubMed

Insights

Inositol hexaphosphate (IP6) increases anti-proliferative PKCdelta, upregulates p27Kip1, and reduces pRb phosphorylation, suggesting its potential as a novel breast cancer therapeutic.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Inositol hexaphosphate (IP6) is a natural carbohydrate with known anti-cancer properties.
  • IP6's mechanism in modulating cell cycle proteins requires further elucidation.

Purpose of the Study:

  • To investigate the effects of IP6 on key signaling pathways and cell cycle proteins in breast cancer cells.
  • To determine the role of protein kinase C delta (PKCdelta) in IP6-mediated cellular changes.

Main Methods:

  • Treatment of MCF-7 and MDA-MB 231 breast cancer cells with pharmacological and physiological doses of IP6.
  • Evaluation of PKC isoforms, PI3-K/Akt, and ras/Erk1/2 signaling pathways.
  • Analysis of cell cycle regulatory proteins p27Kip1 and pRb phosphorylation.
  • Utilized specific inhibitors for PKC delta, MEK/Erk, and PI3K/Akt pathways.

Main Results:

  • IP6 significantly increased expression and activity of PKCdelta.
  • IP6 decreased activity of Erk1/2 and Akt signaling pathways.
  • IP6 elevated p27Kip1 protein levels and reduced pRb phosphorylation.
  • PKCdelta mediated IP6's effects on p27Kip1, pRb, and apoptosis.

Conclusions:

  • IP6 acts as a therapeutic modulator by targeting PKCdelta and p27Kip1 in breast cancer.
  • IP6 demonstrates potential for novel breast cancer therapy, impacting cell cycle regulation and apoptosis.
  • PKCdelta plays a crucial role in mediating the anti-cancer effects of IP6.

More Related Videos

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC09:01

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC

Published on: June 26, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...